The article title identifies a research program aimed at reprogramming macrophage responses using nanotherapeutic strategies that target both immunometabolism and microbial factors to treat sepsis. Investigators reported the study under the journal Signal Transduct Target Ther, with bibliographic identifiers PMID 42901916 and DOI 10.1038/s41392-026-02947-3. The supplied PubMed page metadata confirms the publication date (2026 Oct 21) and the author list, but the abstract and experimental details were not included in the text available for review. Because the public record excerpt lacks the abstract and results, this summary limits itself to the study’s stated focus and to documented bibliographic information.
Multiple authors contributed to the manuscript. The PubMed metadata lists affiliations spanning School of Pharmaceutical Engineering, Northwestern Polytechnical University laboratories of cellular metabolism, Research & Development institutes, and the Institute of Materia Medica among others. Several authors are noted as having contributed equally. The article therefore represents a multi-institutional collaboration spanning pharmaceutical engineering and cellular metabolism research groups in China. The provided page includes contact details for corresponding authors in the metadata. The source did not provide additional author disclosures or a conflict-of-interest statement in the excerpt available here.
The PubMed entry supplies standard citation metadata: journal name, volume and issue, DOI, PMID, author list, and institutional affiliations. That information is explicit and recorded in the source text. The source did not include the article abstract, experimental methods, results, numerical endpoints, statistical analyses, preclinical or clinical status, dosing regimens, safety or adverse-event findings, or other outcome measures. The absence of those sections in the supplied content prevents extraction of efficacy or safety conclusions. Readers must consult the full journal article to access primary data, detailed methods, and the authors’ conclusions.
The title implies two mechanistic axes: immunometabolic modulation and microbial modulation. Reprogramming macrophages therapeutically typically aims to shift innate immune phenotypes—reducing pathological hyperinflammation or reversing immunoparalysis—so the proposed approach likely targets immune-cell metabolism and host–microbe interactions. The phrase “nanotherapeutic” signals use of engineered delivery systems or nanomaterials to modify macrophage biology or to deliver immunomodulatory cargo. However, the PubMed excerpt did not specify what nanomaterials were used, which immunometabolic pathways were targeted, whether microbial modulation refers to microbiome editing, antimicrobial delivery, or pathogen-sensing manipulation, or how these strategies were combined experimentally. The source text did not report whether the work was limited to in vitro assays, animal models, or included any human data.
The supplied PubMed content leaves multiple essential clinical and experimental questions unanswered. The source did not report:
Because these elements are absent from the provided record, no claims about efficacy, mechanism, or translational readiness can be made from this metadata alone. Interested clinicians and researchers should retrieve the full text via the DOI or through institutional access to review methods, datasets, and author interpretations. The next verifiable steps documented in the PubMed entry are the bibliographic identifiers; the full article will contain the experimental details necessary to evaluate clinical relevance, reproducibility, and safety.